BioTuesdays

Tag - GRTS

Gritstone Oncology

BTIG cuts Gritstone Oncology PT to $17 from $31

BTIG reduced its price target for Gritstone Oncology (NASDAQ:GRTS) to $17 from $31, citing interim results from two Phase 1 clinical trials, GRANITE and SLATE, evaluating personalized and off-the-shelf neoantigen...

Gritstone Oncology

HCW starts Gritstone Oncology at buy; PT $17

H.C. Wainwright launched coverage of Gritstone Oncology (NASDAQ:GRTS) with a “buy” rating and $17 price target. The stock closed at $11.64 on March 6. Gritstone is focused on developing novel neoantigen-targeting...

Gritstone Oncology

BTIG starts Gritstone Oncology at buy; PT $26

BTIG launched coverage of Gritstone Oncology (NASDAQ:GRTS) with a “buy” rating and $26 price target. The stock closed at $15.17 on Oct. 22. Gritstone is a clinical-phase oncology company that specializes in focusing a...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.